Related Experiment Video
Updated: Mar 1, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Assessment of GSK1904529A as a promising anti-osteosarcoma agent
Hao-Dong Fei1, Qi Yuan2, Li Mao2
1Department of Orthopedics, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, China.
Abstract:
The insulin growth factor-I receptor (IGF1R) signaling is a key mechanism for osteosarcoma (OS) cell proliferation. GSK1904529A is a novel small molecule IGF1R kinase inhibitor. Its activity against OS cells was tested. In both established OS cell lines (Saos-2 and MG-63) and primary human OS cells, treatment with GSK1904529A (at nM concentrations) significantly inhibited cell proliferation. At the molecular level, GSK1904529A almost completely blocked IGF1R activation in OS cells, and inhibited downstream AKT-ERK activation. IGF1R silence by targeted shRNA also inhibited AKT-ERK activation and Saos-2 cell proliferation. Significantly, GSK1904529A was unable to further inhibit proliferation of IGF1R-silenced Saos-2 cells. In vivo, GSK1904529A administration orally inhibited Saos-2 tumor growth in nude mice. Together, these results suggest that targeting IGF1R by GSK1904529A inhibits OS cell growth in vitro and in vivo.
Insights
The novel inhibitor GSK1904529A effectively halts osteosarcoma (OS) cell growth by blocking insulin growth factor-I receptor (IGF1R) signaling. This targeted approach shows promise for treating OS both in lab studies and in animal models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Insulin growth factor-I receptor (IGF1R) signaling is crucial for osteosarcoma (OS) cell proliferation.
- Targeting key signaling pathways offers a potential therapeutic strategy for OS.
Purpose of the Study:
- To evaluate the efficacy of GSK1904529A, a novel IGF1R kinase inhibitor, against osteosarcoma (OS) cells.
- To investigate the molecular mechanisms underlying GSK1904529A's anti-cancer effects in OS.
Main Methods:
- Treatment of established and primary human OS cells with GSK1904529A.
- Assessment of cell proliferation, IGF1R activation, and downstream signaling (AKT-ERK).
- In vivo studies using a xenograft mouse model with Saos-2 cells.
Main Results:
- GSK1904529A significantly inhibited OS cell proliferation at nanomolar concentrations.
- The inhibitor effectively blocked IGF1R, AKT, and ERK activation in OS cells.
- GSK1904529A demonstrated significant inhibition of Saos-2 tumor growth in vivo.
Conclusions:
- Targeting IGF1R with GSK1904529A is a viable strategy to inhibit osteosarcoma cell growth.
- GSK1904529A exhibits potent anti-tumor activity both in vitro and in vivo.
- The drug's mechanism involves the inhibition of the IGF1R/AKT/ERK signaling pathway.
